Key Drivers
- Liquidity cushion
- Margin pressure
- Cash conversion
AIAI Summary
PCRX is evolving from a mature pain franchise into a cash-generative platform with meaningful upside from the UnitedHealthcare access win and early PCRX-201 data, but the lowered revenue guide means investors should focus on whether coverage gains and pipeline progress translate into actual prescription growth before paying for reacceleration.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity cushion
- •Margin pressure
- •Cash conversion
PCRX has strong liquidity and cash flow with manageable leverage, but thin earnings power and a rich valuation make the stock look fully priced.
Price Behavior
Key Price Behavior Insights:
- •Trend reversal
- •Oversold risk
- •Weak support
PCRX turned sharply bearish over the last month, with lower highs/lower lows, resistance at $24.40-$25.00, and only a possible oversold bounce as near-term relief.
Fast drop from $27.62 to $23.00 signals a sharp reversal and rising near-term downside pressure
Sentiment & News
Key News Insights:
- •Earnings beat
- •Pipeline advancement
- •Sales outlook cut
Pacira beat Q2 earnings and revenue estimates and advanced PCRX-201, but its lowered 2026 sales outlook keeps the stock outlook cautious.
The news is mildly positive for execution and pipeline momentum, but the lowered guidance likely caps near-term upside for PCRX
Similar Companies in Healthcare
Other companies in the same sector with AI ratings